-16.3%
UNH vs MRNA
+34.8%
-51.1%
-61.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.4% | +5.4% | -7.7% | -2.4% |
| 7D | -4.5% | -1.1% | -3.5% | -4.5% |
| 30D | -6.5% | +126.1% | -132.7% | -8.3% |
| 3M | -6.0% | +190.0% | -196.0% | -9.6% |
| 6M | +33.7% | +157.2% | -123.6% | +29.2% |
| YTD | +16.4% | +388.2% | -371.8% | +9.0% |
| 1Y | +10.1% | +467.0% | -457.0% | +2.2% |
| 3Y | -16.3% | +36.1% | -52.4% | -22.0% |
| All | -16.3% | +34.8% | -51.1% | -22.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling